News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point

Specialty: Multispecialty
Allergy & Immunology
Anesthesiology
Cardiology
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Medicine
Gastroenterology
General Surgery
Hematology - Oncology
HIV/AIDS
Hospital Medicine
Infectious Diseases
Internal Medicine
Multispecialty
Nephrology
Neurology
Ob/Gyn & Women's Health
Oncology
Ophthalmology
Orthopedics
Pathology & Lab Medicine
Pediatrics
Plastic Surgery
Psychiatry
Public Health
Pulmonary Medicine
Radiology
Rheumatology
Transplantation
Urology
Today on Medscape
Business of Medicine
Medical Lifestyle
Science & Technology
Medical Students
Nurses
Pharmacists
Residents
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      Wednesday, November 29, 2023
      News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point

      From Medscape HIV/AIDS

      Coverage from the

      Controlling the HIV Epidemic with Antiretrovirals Summit 2016

      October 13 - 14, 2016; Geneva, Switzerland

      October 13 - 14, 2016 Geneva, Switzerland
      • HIV Summit New HIV PrEP Options Emerging, but Gold Standard Remains The current priority is to increase the uptake of once-daily oral pre-exposure prophylaxis, because it will likely be about 5 years before long-lasting injectable PrEP drugs make it to market.
        Medscape Medical News, October 17, 2016
      • HIV Summit 90-90-90 HIV Goals Top-of-Mind at Geneva Summit Strategies that will be instrumental for achieving the 90-90-90 HIV targets set by the United Nations, such as treatment for prevention and test and treat, will dominate the summit's agenda.
        Medscape Medical News, October 11, 2016

      Conference News

      Popular News from AIDS 2016

      • Long-Acting Injectable Antiretroviral Safe, Effective Long-Acting Injectable Antiretroviral Safe, Effective The first long-acting injectable antiretroviral regimen is safe and effective at 48 weeks, and patients find it very convenient, new research suggests.
        Medscape Medical News, Jul 25, 2016
      • HIV Vaccine Trial Gets Green Light HIV Vaccine Trial Gets Green Light Immune responses to candidate HIV vaccines in a South African population were so robust that a large phase 2b/3 efficacy trial will be launched.
        Medscape Medical News, Jul 22, 2016
      • Latest HIV Cure Data Expose Resilience of Infection Latest HIV Cure Data Expose Resilience of Infection Disappointing results from SEARCH 19 and other recent studies are a challenge for researchers, who must balance progress with the fact that most patients are doing well on antiretroviral therapy.
        Medscape Medical News, Jul 19, 2016

      Medscape HIV/AIDS©  WebMD, LLC

      Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

      Find Us On
      About
      About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
      Membership
      Become a Member About You Professional Information Newsletters & Alerts Market Research
      App
      Medscape
      WebMD Network
      Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Medscape UK
      Editions
      English Deutsch Español Français Português UK
      All material on this website is protected by copyright, Copyright © 1994-2023 by WebMD LLC. This website also contains material copyrighted by 3rd parties.